[Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes]. 2013

Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
Setor de Córnea e Cirurgia Refrativa, Hospital Oftalmológico de Sorocaba/Banco de Olhos de Sorocaba, Sorocaba (SP), Brazil. tulioabud@yahoo.com

OBJECTIVE To compare the hypotensive effect in normal eyes of three formulations with different concentrations of brimonidine tartrate: 0.2%; 0.15% and 0.1%. METHODS Prospective, randomized, double-blind study included 60 volunteers, who underwent initial ophthalmologic examination and measurement of intraocular pressure (IOP). Individuals were divided into three groups: (1) brimonidine tartrate 0.15%, (2) brimonidine tartrate 0.2% and (3) brimonidine tartrate 0.1% and randomly received one drop each of drops in each eye. The IOP was measured after 30 minutes, 1 hour and 2 hours. RESULTS We found that all concentrations of brimonidine tartrate significantly reduced intraocular pressure during the study period, with p<0.05. When analyzing the percentage difference of the hypotensive effect of each group, we found no significant difference between the studied groups: (1) -13.50%, (2) -11.50%, (3) -11.90% after 30 minutes (p=0.650); (1) -24.30%, (2) -18.60%, (3) -18.30% after 1 hour (p=0.324); (1) -29.14%, (2) -21.20%, (3) -25.60% after 2 hours (p=0.068). CONCLUSIONS There is no statistically significant difference in intraocular pressure reduction (peak period) between the three formulations of brimonidine.

UI MeSH Term Description Entries
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009798 Ocular Hypertension A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma. Glaucoma, Suspect,Hypertension, Ocular,Glaucomas, Suspect,Hypertensions, Ocular,Ocular Hypertensions,Suspect Glaucoma,Suspect Glaucomas
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011810 Quinoxalines Quinoxaline
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068438 Brimonidine Tartrate A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate,5-bromo-6-(imidazolidinylideneamino)quinoxaline,5-bromo-6-(imidazolin-2-ylamino)quinoxaline,AGN 190342,AGN-190342,Alphagan,Alphagan P,Brimonidine,Brimonidine Purite,Brimonidine Tartrate (1:1),Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer,Brimonidine Tartrate, (R-(R*,R*))-Isomer,Bromoxidine,Mirvaso,Ratio-Brimonidine,Sanrosa,UK 14,304,UK 14,304-18,UK 14304,UK 14308,UK-14,304-18,UK-14,308,UK-14304,AGN190342,Ratio Brimonidine,UK 14,304 18,UK 14,30418,UK 14,308,UK14,30418,UK14,308,UK14304

Related Publications

Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
August 2004, Journal of cataract and refractive surgery,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
April 2001, Journal of cataract and refractive surgery,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
January 1987, Journal of ocular pharmacology,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
December 2005, Ophthalmology,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
December 1998, Archives of ophthalmology (Chicago, Ill. : 1960),
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
June 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
January 2020, International journal of ophthalmology,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
January 2009, Journal of cataract and refractive surgery,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
August 2004, Journal of cataract and refractive surgery,
Tulio Batista Abud, and Marcio Scuoteguazza Filho, and Edjane Souza Santos Oliveira, and Jorge Felipe Abud, and João Antonio Prata Junior
October 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Copied contents to your clipboard!